Metabolic syndrome and the phenotype of multiple sclerosis - 22/08/24
Abstract |
Background |
Comorbidities, particularly vascular comorbidities, have been shown to exacerbate the progression of disability in multiple sclerosis (MS). Metabolic syndrome (MetS) is a cluster of conditions including abdominal obesity, insulin resistance, atherogenic dyslipidemia, and vascular dysfunction, which contribute to vascular morbidity and chronic inflammation.
Objective |
To describe the characteristics of MetS in a cohort of MS patients and evaluate its relationship with the MS phenotype.
Methods |
A monocentric cohort study was conducted on MS patients, collecting demographic, clinical, radiological, and therapeutic data, as well as metabolic data including waist circumference, blood pressure, serum triglycerides, high-density lipoprotein cholesterol, and fasting blood glucose.
Results |
Among the 84 patients included in the study, 27% were diagnosed with MetS. MetS was found to be associated with secondary progressive MS (SPMS). Patients with SPMS had a higher prevalence of MetS compared to those with relapsing-remitting MS (RRMS), even after adjusting for disease duration. While MetS was associated with Expanded Disability Status Scale (EDSS) progression in the 3-year period according to univariate analysis, it did not show a significant association with disease activity.
Conclusion |
This study provides evidence supporting the connection between MetS and the progression of disability in MS, independent of disease relapse activity.
Le texte complet de cet article est disponible en PDF.Keywords : Multiple sclerosis, Metabolic syndrome, Relapsing-remitting multiple sclerosis, Secondary progressive multiple sclerosis, Abdominal obesity, Waist circumference
Plan
Vol 180 - N° 7
P. 673-681 - septembre 2024 Retour au numéro
Article précédent
- Transthyretin amyloid polyneuropathy in France: A cross-sectional study with 413 patients and real-world tafamidis meglumine use (2009–2019)
- D. Adams, P. Cintas, G. Solé, C. Tard, C. Labeyrie, A. Echaniz-Laguna, C. Cauquil, Y. Pereon, L. Magy, R. Juntas Morales, J.C. Antoine, E. Lagrange, P. Petiot, M. Mallaret, B. Francou, A. Guiochon-Mantel, A. Coste, O. Demarcq, C. Geffroy, V. Famelart, J Rudant, M Bartoli, E. Donal, O. Lairez, J.C. Eicher, M. Kharoubi, S. Oghina, J.N. Trochu, J. Inamo, G. Habib, F. Roubille, A. Hagège, F. Morio, E. Cariou, J. Adda, M.S. Slama, P. Charron, V. Algalarrondo, T. Damy, S. Attarian
- Association of clopidogrel resistance and ABCD-GENE score with long-term clinical prognosis in patients with ischemic stroke or TIA
- Y. Kang, L. Guo, Q. Li, C. Liu, W. Jin, M. Huang, Y. Liu, C. Tang, J. Zhu, L. Zhang
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?